Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial

American Journal of Epidemiology

Volumn 172, Issue 1, 2010, Pages 107-115

  Cole, Stephen R ^a   Stuart, Elizabeth A ^a  

^a IL   (United States)

Author keywords

Bias; Bias (epidemiology); Causal inference; External validity; Generalizability; Randomized trials; Standardization

Indexed keywords

HEALTH RISK; HETEROGENEITY; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; MONTE CARLO ANALYSIS; PARTICIPATORY APPROACH; PUBLIC HEALTH; STANDARDIZATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; COMMUNITY SAMPLE; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; EXTERNAL VALIDITY; FEMALE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLING; SIMULATION; TARGET POPULATION; UNITED STATES; CONFIDENCE INTERVAL; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; INCIDENCE; METHODOLOGY; MIDDLE AGED; MONTE CARLO METHOD; PROPORTIONAL HAZARDS MODEL; PUERTO RICO; RISK; RISK FACTOR; STANDARD;

UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIAS (EPIDEMIOLOGY); CONFIDENCE INTERVALS; EVIDENCE-BASED MEDICINE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MONTE CARLO METHOD; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PUERTO RICO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; UNITED STATES;

EID: 78651467125     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq084     Document Type: Article

References (55)

1. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006; 60(7):578-586.
2. Cole SR, Frangakis CE. The consistency statement in causal inference: a definition or an assumption? Epidemiology. 2009;20(1):3-5.
3. VanderWeele TJ. Concerning the consistency assumption in causal inference. Epidemiology. 2009;20(6):880-883.
4. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656-664.
5. Robins JM, Morgenstern H. The foundations of confounding in epidemiology. Comput Math Appl. 1987;14:869-916.
6. Greenland S. Randomization, statistics, and causal inference [see comments]. Epidemiology. 1990;1(6):421-429.
7. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5): 615-625.
8. Szklo M. Population-based cohort studies. Epidemiol Rev. 1998;20(1):81-90.
9. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663-694.
10. Greenhouse JB, Kaizar EE, Kelleher K, et al. Generalizing from clinical trial data: a case study. The risk of suicidality among pediatric antidepressant users. Stat Med. 2008;27(11): 1801-1813.
11. Weisberg HI, Hayden VC, Pontes VP. Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality? Clin Trials. 2009;6(2):109-118.
12. Frangakis C. The calibration of treatment effects from clinical trials to target populations. Clin Trials. 2009;6(2): 136-140.
13. Gandhi M, Ameli N, Bacchetti P, et al. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS. 2005; 19(16):1885-1896.
14. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9(2):117-125.
15. Miettinen OS. Standardization of risk ratios. Am J Epidemiol. 1972;96(6):383-388.
16. Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. New York, NY: Lippincott-Raven; 2008.
17. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11): 725-733.
18. Sommer A, Zeger SL. On estimating efficacy from clinical trials [published erratum appears in Stat Med. 1994;13(18): 1897].
19. Stat Med. 1991;10(1):45-52.
20. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779-788.
21. Cain LE, Cole SR. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. Stat Med. 2009;28(12):1725-1738.
22. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-529.
23. Subpopulation estimates from the HIV incidence surveillance system - United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(36):985-989.
24. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol. 1995; 141(2):166-172.
25. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280(1): 42-48.
26. Cole SR, Chu H, Brookmeyer R. Confidence intervals for biomarker-based human immunodeficiency virus incidence estimates and differences using prevalent data. Am J Epidemiol. 2007;165(1):94-100.
27. Karon JM, Song R, Brookmeyer R, et al. Estimating HIV incidence in the United States from HIV/AIDS surveillance data and biomarker HIV test results. Stat Med. 2008;27(23):4617-4633.
28. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B). 1972;34:187-220.
29. Cox DR. Partial likelihood. Biometrika. 1975;62(2):269-276.
30. Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite universe. J Am Stat Assoc. 1952;47(260):663-685.
31. i. J Off Stat. 1992;8(2): 183-200.
32. Binder DA. Fitting Cox's proportional hazards models from survey data. Biometrika. 1992;79(1):139-147.
33. Lin DY. On fitting Cox's proportional hazards model to survey data. Biometrika. 2000;87(1):37-47.
34. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560.
35. Haneuse S, Schildcrout J, Crane P, et al. Adjustment for selection bias in observational studies with application to the analysis of autopsy data. Neuroepidemiology. 2009;32(3): 229-239.
36. Pan Q, Schaubel DE. Evaluating bias correction in weighted proportional hazards regression. Lifetime Data Anal. 2009; 15(1):120-146.
37. Hoggatt KJ, Greenland S, Ritz BR. Adjustment for response bias via two-phase analysis: an application. Epidemiology. 2009;20(6):872-879.
38. White HA. Maximum likelihood estimation of misspecified models. Econometrica. 1982;50(1):1-25.
39. Hanley JA, Negassa A, Edwardes MD, et al. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157(4): 364-375.
40. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84(408):1065-1078.
41. Robins JM. Marginal structural models. 1997 Proceedings of the Section on Bayesian Statistical Science. Alexandria, VA: American Statistical Association; 1998:1-10.
42. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75(1):45-49.
43. Lane PW, Nelder JA. Analysis of covariance and standardization as instances of prediction. Biometrics. 1982;38(3): 613-621.
44. Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc. 1987;82(398):387-394.
45. Greenland S. Estimating standardized parameters from generalized linear models. Stat Med. 1991;10(7):1069-1074.
46. Stuart EA, Cole SR, Bradshaw CP, et al. The use of propensity scores to assess the generalizability of results from randomized trials. Baltimore, MD: Department of Biostatistics, Johns Hopkins University; 2010. (Working paper 210). (http://www.bepress.com/jhubiostat/paper210).
47. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815- 1826.
48. When to Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373(9672):1352-1363.
49. Cain LE, Hernán MA. Dynamic marginal structural models to find optimal treatment regimes. Am J Epidemiol. 2009; 169(suppl 11):S41.
50. Cole SR, Chu H. Effect of acyclovir on herpetic ocular recurrence using a structural nested model. Contemp Clin Trials. 2005;26(3):300-310.
51. Greenland S, Lanes S, Jara M. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation. Clin Trials. 2008;5(1):5-13.
52. Flanders WD, Klein M. Properties of 2 counterfactual effect definitions of a point exposure. Epidemiology. 2007;18(4): 453-460.
53. Cole SR, Chu H, Nie L. Nonparametric estimator of relative time with application to the Acyclovir Prevention Trial. Clin Trials. 2009;6(4):320-328.
54. Hernán MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13-15.
55. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23(19):2937-2960.